Please login to the form below

Are patient recruitment and retention rates rising or falling?

First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise.

The Tufts Center for the Study of Drug Development (CSDD) collected data on 87 clinical trials from four top-20 pharma companies and one global CRO, comparing the 2019 metrics from 2012. And they found some amazing results:

  • Actual enrolment exceeded planned enrolment in 2019 by 113%, compared to 2012 when trials achieved an average of only 96% of planned enrolment
  • Sites are recruiting faster, with 77% of trials now hitting or beating planned timelines, compared to only 47% previously
  • Trials in North America had the highest planned-to-actual enrolment ratio vs the rest of the world
  • Both North American and Asia/Pacific trials achieved an activation rate of more than 85%
  • Of all sites studied, 87% of proposed early-stage trials, and 85.7 percent of late-stage trials, were able to begin recruiting
  • Respondents’ average number of sites activated in 2019 was 30.5 in North America, 30.1 in Eastern Europe, 27 in Western Europe and 12.5 in Asia/Pacific.

Amazing, right? And according to CSDD, patient involvement in protocol development, mobile data collection devices and virtual trials all contributed to improved recruitment metrics since 2012. It just shows that all the hard work we’re doing as an industry to improve patient recruitment strategies really is paying off.

The hard truth

But, the bad news? Retention rates are falling.

When comparing the 2019 metrics from 2012, CSDD found:
  • In 2019, trial dropout rate rose to 19.1% from 15.3% in late-stage trials globally, with the highest rates occurring in central nervous system (CNS) and oncology trials
  • CNS trial dropout rates grew to 25.9% from 19.2
  • Oncology trial rates grew to 19.3% from 18.2%
  • Vaccine trials experienced a 12.3% dropout rate in 2019
  • Cardiovascular and rare disease trials fared best, with rates of 7% and 6.5% respectively

So, it looks like while recruitment rates have been on the up, this hasn’t translated over to retention. This does make sense when you consider that some companies work so hard to get participants onto their trial in the first place; it can often be forgotten to work on the rest of the patient experience too. And the hard truth is, just because more patients are signing up to take part in a clinical study, there’s nothing stopping them from leaving. So, that’s why retention strategies are just as important as recruitment.

Onwards and upwards

With retention rates taking a serious hit according to the CSDD study, it’s time to make a change. Luckily, there are ways that you can make the experience better for patients and help them want to stay on the study. Here at COUCH Health, we can help you with strategies to do this. Take a look at our white paper to learn more.

This blog was originally published here.

24th September 2020



Company Details

COUCH Health

+44 (0) 330 995 0656

Contact Website

Suite 2.10, Jactin House
24 Hood Street
M4 6WX
United Kingdom

Latest content on this profile

Can eLearning improve patient recruitment and retention?
Some patients will still want to read pages of informed consent forms before joining a clinical trial, or want timely updates on paper rather than a notification on their phone. Whereas some would prefer to see a virtual reminder, watch videos, and take online questionnaires. The point is: there needs to be options. And that’s where eLearning comes in.
COUCH Health
Whats the difference between patient engagement and patient experience?
We all talk a lot about patient engagement and patient experience. And sometimes, these terms are used interchangeably across the industry. But while they’re both important, they’re not the same. So, let’s quickly clear up once and for all what the difference between patient engagement and patient experience is, so we can make sure that we’re doing the best possible job in both areas…
COUCH Health
Building trust in clinical trials whilst it is in the public eye
We’re all well aware that healthcare organisations are generally perceived to be untrustworthy. According to Edelman’s 2018 Trust Barometer, we even saw a clear global decline of public trust in pharma, biotech, hospitals, insurance and consumer health companies.
COUCH Health
Diversity in clinical trials needs to extend beyond COVID-19 vaccine trails
First up, the hard truth is that clinical trial populations are not diverse. People of certain ethnicities, females and the elderly are typically underrepresented in clinical research. And you might ask, “why?”
COUCH Health
Insights from patients during the COVID-19 pandemic
We all know how much the COVID-19 pandemic has affected everyone around the world. And within the healthcare industry, priorities have been re-evaluated and processes changed, to ensure that patients keep receiving care.
COUCH Health
September 2020: diversity and inclusion in clinical trials round-up
Our latest round-up takes a closer look at the different conditions where health disparities are present, such as more women living with multiple sclerosis (MS), and the cancer death rate being highest among Black people vs all other ethnic groups. Plus, there are a couple of articles with important insights about inequalities in LGBTQ+ communities, too.
COUCH Health